Journal
JOURNAL OF HEADACHE AND PAIN
Volume 18, Issue -, Pages -Publisher
BMC
DOI: 10.1186/s10194-017-0813-3
Keywords
Migraine; Tension-type headache; Cluster headache; Neurostimulation; Monoclonal antibodies; Patient-centeredness; Equity of healthcare; Nocebo
Categories
Funding
- Allergan
- Amgen
- Biogen
- Brain Research
- GammaCore
- Genesis Pharma
- Eli Lily
- Merck-Serono
- Novatis
- Roche
- Sanofi-Genzyme
- Teva-Specifar
- Biogen-Genesis
- Elpen
- Pharmathen
- UCB
- Bayer
- Pfeizer
- Novartis
- Allergan Hellas
- Brain Therapeutics (Greece)
Ask authors/readers for more resources
Background: We aimed to explore patients' preferences for headache treatments with a self-administered questionnaire including the Q-No questionnaire for nocebo. Methods: Questionnaires from 514 outpatients naive to neurostimulation and monoclonal antibodies were collected. Results: Patients assessed that the efficacy of a treatment is more important than safety or route of administration. They preferred to use an external neurostimulation device for both acute (67.1%) and preventive treatment (62.8%). Most patients preferred to take a pill (86%) than any other drug given parenterally for symptomatic pharmaceutical treatment. For preventive pharmaceutical treatment, most patients preferred to take a pill once per day (52%) compared to an injection either subcutaneously or intravenously each month (9% and 4%), or three months (15% and 11%). 56.6% of all participants scored more than 15 in Q-No questionnaire indicating potential nocebo behaviors that contributed significantly in their choices. Conclusion: These patient preferences along with efficacy and safety data may help physicians better choose the right treatment for the right person.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available